SLC5A2 and chronic kidney disease: In particular, the use of SGLT2 inhibitors and long-acting GLP1 receptor agonists (GLP1-RAs) is strongly recommended for individuals with an elevated risk of atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and/or heart failure.